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Abstract 
Background: Data on the survival status of older adults on antiretroviral treatment (ART) are scarce in sub-Saharan 
Africa. The objective of this study was to determine the survival status of people aged 50 years and older who were 
HIV-negative, HIV-positive not on ART, and HIV-positive on ART.
Methods: We used three waves of data from the World Health Organisation Study on Global Ageing and adult 
health- Well Being of Older People Study cohort in Uganda, conducted in 2009, 2012–2013 and 2015–2016. The 
cohort included HIV-negative and HIV-positive persons aged 50 years and older recruited from multiple rural and peri-
urban sites in Uganda. Data were collected using interviewer-administered questionnaire. Time-dependent ART data 
were collected from medical records using a data-abstraction form. This study was conducted before the universal 
test and treat policy came into effect. We fitted Cox survival models to estimate hazard ratios to compare the risk of 
death between groups, adjusted for age, sex, marital status and hypertension.
Results: Of 623 participants, 517 (82.9%) of respondents had follow-up data and were included in this analysis. We 
observed 1571 person-years of follow-up from 274 people who were HIV-negative, and 1252 from 243 who were 
HIV-positive. The estimated mortality adjusted hazard ratio (aHR) was 1.89 (95% CI 1.0–3.4; p = 0.04) among people 
living with HIV compared to HIV-negative people. The aHR for mortality among people receiving ART compared with 
HIV-negative people was 1.75 (95% CI 0.9–3.5). People who were HIV-positive and not receiving ART had the greatest 
risk of death (aHR = 2.09, 95% CI 1.0–4.4 compared with HIV negative participants). The aHR for HIV-positive people 
not receiving ART, compared to those who were on treatment, was 1.19 (95% CI 0.6–2.5).
Conclusion: Older adults living with HIV on ART had a risk of mortality that was nearly twice as high as HIV-negative 
adults. Further analyses of longitudinal data should be done to understand factors that affect the survival of older 
adults on ART.
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adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The number of older people living with human immu-
nodeficiency virus (HIV) is increasing globally [1]. Esti-
mates from the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) for 2013 indicated that around 3.6 
million people aged 50 years and older were living with 
HIV. As of 2017, this estimate was 6.7 million older adults 
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[1]. Even though HIV data availability for older people 
has improved, the 2018 UNAIDS estimates for those aged 
50 years and older rely heavily on extrapolations of data 
for younger age groups [2]. Prior to 2010 global figures 
were found to underestimate the total number of people 
aged 50 years and older living with HIV globally [3]. After 
2010, UNAIDS changed its models for estimating the 
number of older adults living with HIV. There may still 
be underestimates but we do not have consistent data 
on this. Results from a study following cohorts between 
1998 and 2011 in Zimbabwe showed that HIV prevalence 
among those aged 45–54 years was higher than in those 
aged 15–44 years between 2006/08 and 2009/11 [4].
In 2005 in the USA, 15% of the new HIV diagnoses and 
24% of those living with HIV were aged 50 years and over. 
In 2015, 17% of new diagnoses and 47% of the people liv-
ing with HIV in the USA were aged 50  years and older 
[5]. In sub-Saharan Africa (SSA) where the largest num-
bers of people living with HIV live, the number of people 
aged 50  years and older living with HIV has continued 
to increase. In 2017, it was estimated that four million 
people aged 50  years and over were living with HIV in 
SSA [1].With the increasing number of people accessing 
combination antiretroviral therapy (ART) in Africa, these 
numbers are likely to be higher currently.
A number of factors contribute to the increase in the 
number of older people living with HIV, including the 
introduction of effective HIV treatment with ART which 
has significantly prolonged the life expectancy of people 
on ART treatment [6], and older people acquiring new 
HIV infections, especially in SSA where HIV prevention 
campaigns do not target older adults.
An estimated 59% of people living with HIV in 2017 
were on ART [1]. ART prolongs the life expectancy of 
people living with HIV, and as a result of this, populations 
taking ART are living longer now than when antiretrovi-
ral drugs were introduced in Africa in early 2000. Data 
are scarce on how the natural decline in immune func-
tion with age might influence outcomes in older people 
living with HIV. People aged 50 and older on ART have 
good immunological and virological responses [7–10], 
and report better adherence to treatment than younger 
adults [11–13] but studies have reported higher rates of 
disease progression, shorter survival times and higher 
rates of progression to AIDS in older than younger adults 
[14–17]. This has been attributed to late diagnosis and 
treatment of older people living with HIV in addition to 
higher competing mortality risks [8]. In addition, the nat-
ural decline of immune function with ageing might influ-
ence mortality among those newly diagnosed with HIV 
when they are aged 50 years and over as compared with 
those diagnosed younger, who maintain viral load sup-
pression on ART for decades through to older age.
ART has increased life expectancy for those on treat-
ment, and has also improved the health and functioning 
of older adults living with HIV on ART. Studies following 
older people with and without HIV in both Uganda [18, 
19] and South Africa [20] have demonstrated that older 
people with HIV on ART report the same or even better 
health as compared to their counterparts who are HIV-
negative. Most of these studies have been cross-sectional 
studies and have been conducted in high-income coun-
tries, leaving an information gap on survival of older peo-
ple on ART in the African region. The objective of this 
paper was to document the survival rates of people aged 
50+ years by HIV and treatment status.
Data and methods
SAGE‑WOPS HIV study
The SAGE-WOPS (Study on global AGEing and adult 
health –Wellbeing of Older People Study) HIV study 
is a cohort study of people aged 50+ years established 
in Uganda in 2009 [18, 21], as a collaboration between 
WHO and the Medical Research Council/Uganda Virus 
Research Institute and London School of Hygiene and 
Tropical Medicine Uganda Research Unit. Three survey 
waves were conducted within the cohort.
SAGE-WOPS wave 1 was conducted in 2009–2010 [18] 
using a random-selection of the surveillance population. 
The surveillance population included the General Popu-
lation Cohort [22–24] and the Entebbe cohort [25–27]. 
Initial recruitment into the cohort was in 2009 in two 
districts (Kalungu and Masaka) in Southwest Uganda 
and a third (Wakiso) near Entebbe town on the shores 
of Lake Victoria. The initial study population consisted 
of 510 participants aged 50 years and over who were liv-
ing with and without HIV. The study population included 
both those on treatment with ART and those waiting to 
start ART according to the government of Uganda ART 
treatment guidelines at that time (WHO stage IV disease 
irrespective of CD4 cell count, WHO stage III disease 
if CD4 cell test testing was unavailable; if available CD4 
cell counts ≤ 200 cells/mm3. Other criteria were CD4 
cell counts above 200 but below 350 cells/mm3 in those 
co-infected with pulmonary tuberculosis or have severe 
bacterial infection and women who were pregnant. The 
last criterion was WHO stage 1 and 2 with CD4 cell 
counts ≤ 200 cells/mm3. HIV-positive people and HIV-
negative people were selected from the same study set-
tings and cohorts.
During SAGE-WOPS wave 2 (2012–2013), we visited 
households of wave 1 participants. If participants were 
still living in the study area, we re-interviewed them. If 
the respondent was not available, we obtained informa-
tion about the survival status. Of the 510 wave 1 par-
ticipants, 63 (12.4%) had died and 148 (29.0%) were 
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not seen during wave 2 [28]. In wave 2, we recruited an 
additional 100 older people living with HIV attending 
The AIDS Support Organisation (TASO) that provides 
care to people living with HIV in Masaka town. The 
new participants were randomly selected from people 
aged 50 years or older attending TASO. These additional 
recruits were to increase the number of people living 
with HIV in the cohort. In order to avoid misclassifica-
tion of the study groups, all older people who were HIV-
negative in SAGE-WOPS1 were retested for HIV using 
the Uganda Ministry of Health algorithms for rapid HIV 
testing. Study participants were provided pre- and post-
test counselling in accordance with the Uganda Ministry 
of Health HIV testing policy. Those found positive were 
referred to both private and public health care facilities 
in the study setting that are accredited with the Ministry 
of Health in Uganda to provide ART to people with HIV.
In SAGE-WOPS wave 3 (2015–2016), all participants 
in waves 1 or 2 who were still living in the study area were 
tracked and re-interviewed. In addition, all people who 
had become aged 50 years or older who were living with 
HIV within one of the MRC/UVRI and LSHTM HIV sur-
veillance sites in Southwest Uganda (Kalungu) were eligi-
ble for the cohort and interviewed.
In all 3 survey rounds, data on demographic charac-
teristics of study participants were collected. In addition, 
during SAGE-WOPS wave 3, data on survival status for 
all participants who were seen in the previous SAGE-
WOPS waves were collected.
For participants who died between the baseline sur-
vey and the follow-up surveys, mortality data were col-
lected using a standardized verbal autopsy questionnaire 
adapted from the World Health Organization verbal 
autopsy questionnaire [29]. The resulting data included 
the date of death and the suspected cause of death. We 
obtained notification of deaths from the next of kin or 
any other close relative of the deceased.
ART-related data were collected through review of clin-
ical files of participants who were on ART treatment and 
time-updated ART status was used in the analysis. These 
were available only for study respondents recruited from 
Kalungu district (about half of the participants on ART). 
It was not possible for the study team to review files for 
participants recruited from Wakiso district because they 
were receiving ART treatment from multiple health care 
facilities and their ART records were incomplete and 
diverse.
Hypertension status For all study participants (all 
three waves), systolic and diastolic blood pressures 
were measured three times at recruitment in WOPS 
with participants in a sitting position using a Boso 
Medistar-S-wrist blood pressure monitor. An aver-
age BP for the three readings was computed and used 
in the analysis. Hypertension was defined accord-
ing to the World Health Organization criteria (systolic 
blood pressure ≥ 140  mmHg and/or diastolic blood 
pressure ≥ 90 mmHg).
HIV testing
At each study wave, follow-up participants who were 
HIV-negative in the previous wave were retested in order 
to avoid misclassification. HIV testing was done follow-
ing the Ministry of Health of Uganda testing algorithm. 
The algorithm for HIV rapid testing consisted of an ini-
tial screening with the rapid test, Determine HIV1/2. If 
the test result was negative, the participant was given a 
negative diagnosis with no further rapid testing. If the 
test result was positive, the sample was retested with the 
rapid test HIV 1/2 Stat-Pak. If both tests gave a positive 
result, the participant was given a diagnosis of HIV-pos-
itive with no further rapid testing. If the tests gave dis-
cordant results (i.e. one positive and the other negative), 
the sample was further evaluated with the rapid test Uni-
Gold Recombinant HIV-1/2. For those samples assessed 
by all three tests, two positive test results were inter-
preted as a positive diagnosis. If two of the three tests 
gave negative results, then the participant was considered 
to be HIV-negative.
Ethical issues
We obtained ethical clearance for all SAGE-WOPS waves 
from the Uganda Virus Research Institute Research and 
Ethics Committee and from the Uganda National Council 
for Science and Technology. Approval was also obtained 
from the WHO Ethical Review Committee (RPC-149). 
All study respondents gave a written/thumb printed con-
sent after the study interviewers read for them an infor-
mation sheet with details about the study.
Statistical methods
In this paper, the study population was restricted to 
those who were present in Wave 1 or Wave 2 and had at 
least one follow-up visit, or who died during the follow-
up period. The outcome of interest was overall survival, 
specifically investigating two binary time-updated expo-
sures: HIV status and ART status (among those who were 
HIV-positive). Primary analysis was performed using 
time-to-event methods: entry was the date of interview 
in Wave 1, and exit was either date of death or date last 
seen (date of last SAGE-WOPS interview).
The initial analysis was descriptive, including Kaplan–
Meier plots, number of deaths tabulations, and the per-
son-years at risk for each group. To assess the impact of 
HIV on overall survival, we fitted a Cox survival model, 
thus estimating a hazard ratio (HR) to compare the risk 
of death between groups. We assessed the impact of ART 
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treatment by including a three-level indicator variable to 
indicate if a person was HIV-negative, HIV-positive and 
on ART or HIV-positive and not on ART. We controlled 
for age by using date of birth as the origin in the model. 
HIV sero-status and ART treatment status were recorded 
at each wave and included in the analysis as time-varying 
covariates. We adjusted for key confounders (sex, mari-
tal status (currently married or not) and hypertension) 
as well as current age. Due to sparse data, we could not 
include further covariates in the model, judged by the 
rule of thumb of ten events per parameter. As an explora-
tory investigation, we examined if the effect of HIV dif-
fered by sex by including an interaction between HIV and 
sex in the regression model.
We carried out two further analyses. First, we examined 
the effect of ART treatment in a dataset restricted to just 
people living with HIV. Second, to confirm the results 
from the main analysis we fitted an exponential survival 
model, split into ten-year age bands to compare people 
of similar ages and to estimate adjusted risk ratios (RR) 
for the two main exposures listed above. All estimates are 
reported with a 95% confidence interval (CI). Stata ver-
sion 14.2 (Arizona, USA) was used for all analyses.
Results
In SAGE-WOPS wave 1, a total of 510 people was 
recruited; a further 126 were recruited for wave 2, giv-
ing a total of 636 potentially eligible for this study. Of 
these, 10 were ineligible as they were younger than 50 at 
recruitment and 3 had a reported date of death through 
surveillance earlier than recruitment. Of the remain-
ing 623 participants, 71 did not have follow-up data and 
were not reported as having died, so were excluded from 
the analysis, and 35 had missing data and were excluded 
from the complete case analysis (8 due to missing data 
on sex, 27 with missing date of birth). For flow of partici-
pants, refer to Fig. 1.
Of the 517 respondents included in this analysis, the 
majority were women (61%); the median age at entry was 
61 years (Table 1). Participants who were lost to follow-
up were less likely to be married and more likely to be 
hypertensive, compared to people included in this analy-
sis (Table 1).
In this analysis, we included 243 people who were living 
with HIV; just one person seroconverted during the study 
period, between Wave 2 and Wave 3. The proportion of 
people living with HIV who were on ART increased from 
50.9% (86/169) at wave 1 to 78.1% (157/201) at wave 2, 
and 72.2% (143/198) at wave 3.
We observed a total of 2823 person-years of follow-
up; 1571 from people who were HIV-negative, and 1252 
from those were HIV-positive. HIV negative respondents 
were significantly older than HIV positive participants 
at enrolment (median age 69.2  years vs 56.6  years; 
p < 0.0001). HIV negative participants were also less likely 
to be female and more likely to be hypertensive, and all 
analyses are adjusted for age, sex and hypertension. In 
addition, loss to follow-up was differentially associated 
with marital status by HIV status and this was adjusted 
for.
Overall survival by HIV status
We were notified of 74 (14.3%) deaths among the 517 
study participants. Of these, 45 were among people who 
were HIV-negative (16.9% of participants who were 
HIV-negative at baseline) and 29 were among people liv-
ing with HIV at baseline (15.4%). The mortality rate was 
28.6 (95% CI 21.4–38.4) per 1000 person-years among 
HIV-negative participants, and 23.2 (95% CI 16.1–32.3) 
among people living with HIV, reflecting the older age at 
enrolment of HIV negative participants. The median age 
of death in the two groups was 85 and 77 years, respec-
tively. After adjusting for age, marital status and hyper-
tension, there was evidence of poorer survival among 
HIV-positive than HIV-negative respondents (p = 0.02; 
Fig.  1), with an estimated adjusted HR of 1.89 (95% CI 
1.0–3.4; Table 2). There was no evidence of effect-modifi-
cation of this association by sex (p = 0.68). The estimated 
adjusted rate ratio from the exponential survival model 
was similar (aRR = 1.70; 95% CI 1.0–3.0; p = 0.07).
HIV-positive participants not receiving ART had the 
greatest relative risk of death (aHR 2.09, 95% CI 1.0–4.4, 
p = 0.05, compared with HIV negative participants; 
Table  3). HIV-positive participants on ART also had a 
higher relative risk of death than HIV-negative people 
(aHR = 1.75, 95% CI 0.9–3.5, p = 0.11; Table 3), although 
this was not statistically significant. The aHR for HIV-
positive people not receiving ART, compared to those on 
ART was 1.19 (95% CI 0.6–2.5). The adjusted RR from an 
exponential model were similar.
Overall survival by ART status
Among the 243 people living with HIV, we observed 29 
deaths; 12 were among people not receiving ART at the 
visit prior to their death (from 449 person-years of obser-
vation), and 17 were respondents who reported using 
ART at their last visit to the health facility (802 person-
years). The rate of death was 26.7 (95% CI 15–47; median 
age of death 77  years) per 1000 person years and 21.2 
(95% CI 13–34; median age of death 77  years) among 
the two groups respectively. A log-rank test comparing 
the two groups found no evidence of a difference in sur-
vival (p = 0.85), although we note the small number of 
deaths would reduce power to detect any difference here. 
A Kaplan–Meier plot of survival times is shown in Fig. 2 
(Kaplan–Meier plot of overall survival, by HIV treatment 
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636 participants recruited in 
WOPS 1 and WOPS 2 
623 
517 Final sample 
626 
552 
10 excluded age less than 50 
3 excluded wrong dates of birth  
71 excluded, no follow up data 
Fig. 1 Flow of participants
Table 1 Baseline characteristics of study participants and those who were lost to follow-up
Characteristic HIV-negative HIV-positive LTFU
HIV-negative HIV-positive
N (%) 274 (100%) 243 (100%) 36 (14.6%) 35 (14.4%)
Wave 1 266 (97.1%) 169 (69.5%) 34 21
Wave 2 214 (78.1%) 201 (82.7%) 2 14
Wave 3 205 (74.8%) 200 (82.3%) – –
Female sex 98 (35.8%) 102 (42.0%) 12 (16.9%) 16 (22.5%)
Married 95 (34.7%) 79 (32.5%) 7 (9.9%) 10 (14.1%)
Hypertensive 51 (18.6%) 20 (8.2%) 14 (19.7%) 4 (5.6%)
ART 0 (%) 155 (63.8%) 0 (0.0%) 26 (74.3%)
Age at entry; median (IQR) 69.2 (60–77) 56.6 (53–62) 69 (60–78) 57 (52–63)
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status). The estimated aHR was 0.85 (95% CI 0.4–1.8; 
p = 0.67). There was no evidence (p = 0.45) of a differing 
effect of ART between men and women. The estimated 
aRR from an exponential model was similar (aRR = 0.79; 
95% CI 0.4–1.7).
Discussion
In this study, we explored survival by HIV and HIV 
treatment status in people aged 50 years and over. After 
adjusting for age and other key confounders, partici-
pants aged 50  years and over who were HIV-negative 
had better survival than people aged 50 years and over 
who were HIV-positive and were on ART or were still 
waiting to initiate ART. However, among HIV positive 
participants, there was no evidence of a difference in 
survival by ART status.
From the previous cross-sectional analyses from 
WOPS, we have consistently established that older peo-
ple who are living with HIV reported similar or better 
health status compared to those who are HIV-negative 
of the same age [18, 30]. The possible explanation for 
this has been the frequent interaction of HIV-positive 
older persons with the health-care facilities as opposed 
to those who are HIV-negative who may take not visit 
health care facilities regularly [31].
Older people who had not yet initiated ART had 
similar survival with those who were already on ART. 
One possible explanation for this could be the fact that 
we were unable to adjust for baseline CD4 cell counts: 
these data on baseline CD4 cell counts were not avail-
able for most of our study participants due to the fact 
that by 2004 when ART was introduced in the study 
population patients could be started on ART based 
on other criteria, irrespective of if they had a known 
baseline CD4 cell count. It should however be noted 
that all the participants who were on ART had been 
on ART for 6 months or more and those who had not 
yet started ART were still healthy without any docu-
mented opportunistic disease. Some of the factors that 
may influence survival of older patients on ART include 
the time of HIV diagnosis, the period the patient has 
been on treatment, availability of opportunistic infec-
tions and more importantly adherence to antiretroviral 
medication. However, most of these variables were not 
related to survival in this paper. Other factors include 
co-existence of multimorbidity in patients with HIV 
infection (Fig. 3). 
Table 2 Results from  Cox model for  risk of  death by  HIV 
status
a Adjusted for age, sex, marital status and hypertension
N = 517 Adjusted hazard 
 ratioa
95% CI p value
HIV negative 1
HIV-positive 1.89 1.03–3.45 0.04
Female sex 0.57 0.33–0.98 0.04
Married 0.61 0.33–1.13 0.12
Hypertensive 1.33 0.71–2.48 0.38
Table 3 Results from  Cox model for  risk of  death by  ART 
status
N = 517 Hazard ratio 95% CI p value
HIV negative 1
HIV-positive, on ART 1.75 0.88–3.47 0.11
HIV-positive, not on ART 2.09 1.00–4.37 0.05
Female sex 0.57 0.33–0.97 0.04
Married 0.61 0.33–1.12 0.11
Hypertensive 1.33 0.71–2.49 0.37
Fig. 2 Overall survival by HIV status
Fig. 3 Overall survival by ART status
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There are limited longitudinal data within SSA 
which cover the health and survival of older people 
living with HIV and on treatment with ART. Some of 
the few longitudinal studies that have been done only 
compared response to ART treatment and survival 
between older adults (50 years and above) and younger 
adults (those aged below 50) [32]. In addition, most of 
these studies have not compared the survival of older 
adults who are HIV-negative to those living with HIV. 
This study contributes to the scanty literature availa-
ble on survival of HIV infected older adults within the 
African region.
There are some limitations to our study. First, we 
collected ART related data by reviewing ART related 
records only from study participants on ART from 
Kalungu district. It was not possible for the study team 
to review files for participants recruited from Wak-
iso district because they were receiving ART treat-
ment from multiple health care facilities and their 
ART records were incomplete and diverse. This could 
have introduced some bias in our analyses. However, 
since participants from Kalungu represent about half 
of all WOPS participants on ART, the bias would be 
minimised. Second, we intended to collect adherence-
related data from all our study participants but this 
was not possible because these adherence data are not 
routinely collected within the facilities where our study 
participants obtain their antiretroviral drugs. In addi-
tion, ART treatment status was recorded at each wave, 
and included in analysis as a time-varying variable. As 
such, we did not know the actual date people started 
ART or stopped ART. Age reporting may be problem-
atic, as older persons often do not know their exact 
age and they do not have birth certificates. Therefore, 
errors in age is possible. In our cohort studies, major 
efforts were made to collect the best possible data on 
age. Most old people in Uganda know major events 
that occurred around the time of their birth. We asked 
for major events and used the dates of these events to 
estimate their age. Date of death through surveillance 
may also not be very accurate as exemplified by 3 par-
ticipants that were excluded because they had reported 
date of death earlier than recruited.
These data were collected before the universal test 
and treat policy was put in place in Uganda. When 
SAGE-WOPS cohort was initiated, those eligible for 
ART initiation were those in WHO clinical stage 3 or 4, 
or those who had a CD4 cell count of less than 200/µL. 
As the cohort enrols for the fourth wave, all the study 
participants who were originally HIV-positive have 
already been initiated on ART following the implemen-
tation of test and treat policy by WHO [33], which has 
been adopted by the Uganda Ministry of Health.
Conclusion
Our study found that older adults living with HIV, includ-
ing those on ART had a risk of mortality that was nearly 
twice as high as HIV-negative older adults. Further analy-
ses of longitudinal data should be done to understand fac-
tors that affect the survival of older adults on ART.
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